50results about "Stomach cancer vaccine" patented technology

Objective methods for detecting and diagnosing intestinal-type gastric cancers are described herein. Also described is method for predicting the presence or absence of lymph node metastasis (i.e., identifying the metastatic phenotype). In one embodiment, the diagnostic method involves the scoring of gene expression profiles that discriminate between lymph node positive tumors and lymph node negative tumors. The predictive score calculated acts as diagnostic indicator that can objectively indicate whether a sample tissue has the metastatic phenotype. The present invention further provides methods of diagnosing intestinal-type gastric cancer in a subject, methods of screening for therapeutic agents useful in the treatment of intestinal-type gastric cancer, methods of treating intestinal-type gastric cancer and method of vaccinating a subject against intestinal-type gastric cancer.

A specific chimeric antigen receptor targeting NKG2DL, its coding sequence, and modified immune response cells, as well as their preparation method and application. The modified immune response cells can effectively target and attack various tumor cells, especially positive tumor cells expressing NKG2DL, and can be used to prepare preparations for treating tumors.

Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis.

The invention discloses an ROBO1 CAR-NK cell carrying a suicide gene as well as a preparation method and application of the ROBO1 CAR-NK cell. In order to improve the safety and controllability of theCAR-NK therapy, a suicide gene switch element is integrated into a genome through a lentiviral transfection technology on the basis of the current ROBO1 CAR-NK cell to form the CAR-NK with the suicide gene. By adding the suicide gene, the CAR-NK cells can be better controlled, and the clinical safety is further improved.

The invention relates to a universal chimeric antigen receptor T cell targeting claudin 18.2, a construction method and an application of the universal chimeric antigen receptor T cell, and belongs tothe technical field of molecular biomedicine. The invention provides a single-chain antibody targeting the claudin 18.2, and the chimeric antigen receptor T cell containing the single-chain antibodytargeting the claudin 18.2. The chimeric antigen receptor targeting the claudin 18.2 can specifically target the claudin 18.2, promote the amplification of the T cell in the body of a patient, efficiently and specifically kill tumor cells, and hardly cause damage to normal cells.

The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

The invention discloses a chimeric antigen receptor of a cell for targeted expression of Claudin 18.2 (CLDN 18.2), and particularly discloses a chimeric antigen receptor with an amino acid sequence as shown in SEQ ID NO.14. The chimeric antigen receptor comprises a Claudin 18.2-targeted single-chain antibody, a hinge region, a transmembrane structural domain and an intracellular signal structural domain. The Claudin 18.2-targeted chimeric antigen receptor disclosed by the invention can achieve effective and specific targeted expression of malignant cells (such as tumor cells) of the Claudin 18.2 surface antigen, so that a more efficient method with fewer side effects and adverse reactions is provided for treating some tumors expressing the Claudin 18.2 surface antigen.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Provided is a chimeric antigen receptor, which comprises a co-stimulatory signal domain composed of an extracellular domain, a transmembrane domain and an intracellular domain, wherein the co-stimulatory signal domain comprises the full length or a fragment of the amino acids of encoded reverse dectin-1 and can treat multiple solid tumors and malignant hematological tumors.

The present invention relates to formulations comprising an anti-PD-L1/OX40 bispecific antibody, in particular to pharmaceutical formulations comprising an anti-PD-L1/OX40 bispecific antibody, a buffer, a stabilizer and a surfactant. In addition, the invention also relates to the use of these formulations for the treatment or prevention of diseases.

The present invention provides a vaccine composition comprising: (i) an adjuvant; and (ii) at least one fusion peptide conjugated to a carrier protein, wherein the carrier protein is the diphtheria toxin variant CRM-197 (GenBank Accession No. and wherein the at least one fusion peptide comprises two or more non- contiguous B cell epitopes of Her2/neu selected from the group consisting of SEQ ID Nos:1-7 and 15-60 and amino acid sequences that have at least 85% identity to any of the foregoing. The present invention also extends to pharmaceutical compositions and methods of using the vaccine and/or pharmaceutical compositions, as herein described, for the treatment or prevention of a cancer characterised by the expression or over-expression of Her2/neu in a patient in need thereof.

The invention relates to a specific chimeric antigen receptor cell armed with a targeted CXCR2 ligand as well as a preparation method and application thereof. Through a method, which uses a recombinant carrier of a chimeric antigen receptor that specifically targets human NKG2DL armed with a targeting CXCR2 ligand to modify a immune response cell, the obtained novel functionalized immune responsecell can effectively attack multiple tumors in a targeted mode; and the functionalized immune response cell can be used to prepare preparations for treating malignant tumors. The engineering immune cells modified by a chimeric antigen receptor that is armed with a targeting CXCR2 ligand and specifically targets human NKG2DL can more easily migrate to a tumor position and continuously kill the tumors in a targeted mode.

The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular gastric cancer, lung cancer, melanoma and bladder cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering the pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.

From gene expression analysis with a long-term recurrence-free group and a recurrence metastasis group of stomach cancer, CHRNB2 and NPTXR were identified as drug discovery targets. Tumor growth was successfully inhibited by an antibody medicine or a nucleic acid medicine targeting CHRNB2 or NPTXR. Furthermore, a polyclonal antibody and a monoclonal antibody linking to CHRNB2 or NPTXR are provided. Since these receptor molecules are novel molecular targets, treatment of cases which the existing therapeutic drugs have no effect on is made possible.

The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of A33 protein. Theantibodies of the present technology are useful in methods for detecting and treating an A33 -positive cancer in a subject in need thereof.

Antibodies that specifically bind to the human tight junction molecule CLDN18.2 and have functional properties that make them suitable for use in antibody-based immunotherapies of a disease associated with aberrant expression of CLDN18.2 are disclosed.

Compositions and treatments for inducing tumor regression by activating inflammasomes in tumor cells and tumor-associated cells. A tumor in a subject is treated by administering a composition to the subject that activates inflammasomes in cells of the tumor and thereby causes tumor cell pyroptosis and tumor regression.

The present invention relates to immunogens directed against lung cancer associated proliferative peptides and growth factors and its uses thereof in conjunction with chemotherapeutics in the early and advanced treatment of various malignant diseases, especially including lung cancers, both small cell lung carcinomas (SCLC), non-small cell lung (NSCLC) cancers and neuroendocrine-type cancers.

The invention relates to a preparation method of Mesothelin chimeric antigen receptor modified T cells with targeted high-intensity tumor killing activity, which comprises the following steps: transforming MSLN-CAR-puro plasmids into escherichia coli competent cells, conducting coating, screening and culturing on a solid culture medium, and extracting plasmids after propagating a grown single colony; preparing human peripheral blood mononuclear lymphocytes (PBMCs); and extracting plasmids, mixing the extracted plasmids, Super PiggyBac Transspoase plasmids and an electrotransfection buffer solution, transfecting PBMC (peripheral blood mononuclear cells), conducting culturing by using an X-VIVO culture medium, activating and amplifying CD3 positive T cells by using CD3/CD28 magnetic beads, and screening and amplifying the transfected T cells. The mesothelin-targeted MSLN-CAR-T cell is constructed through a PiggyBac transposon system, so that the mesothelin-targeted MSLN-CAR-T cell has targeted killing performance on solid tumors and is good in safety, and a research basis is provided for related clinical transformation.